Current Price Disclosure cycle – 2023 April
Page last updated: 18 November 2022
The 2023 October cycle has a data collection period of 1 April 2022 to 30 September 2022.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 11 November 2022.
The reduction day is 1 April 2023.
- Outcomes of Price Disclosure calculations
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations will be published in a legal determination on the Federal Register of Legislation website in December 2022. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2022 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2022 will also take the reduction on 1 April 2023 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes will be published here when the outcomes are also published.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices will be published in December 2022.
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2023 will be published in December 2022. Sponsors can apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices reports will be published in December 2022.
The confirmed prices report will be published in March 2023.
This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.
The brand price reduction report will be published in March 2023.
This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 April 2023. This information is made available to assist patients with understanding how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.